Alkermes Plc (NASDAQ:ALKS) has been given a consensus recommendation of “Hold” by the fifteen research firms that are currently covering the stock, MarketBeat.com reports. Eight research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $64.09.
A number of research analysts recently issued reports on ALKS shares. ValuEngine upgraded Alkermes from a “sell” rating to a “hold” rating in a report on Friday, December 1st. Citigroup set a $62.00 price target on Alkermes and gave the stock a “hold” rating in a report on Thursday, October 26th. BidaskClub raised Alkermes from a “sell” rating to a “hold” rating in a report on Wednesday, December 27th. Credit Suisse Group decreased their price target on Alkermes from $70.00 to $66.00 and set an “outperform” rating for the company in a report on Friday, October 27th. Finally, Barclays set a $50.00 price target on Alkermes and gave the stock a “hold” rating in a report on Thursday, October 26th.
Alkermes (NASDAQ:ALKS) traded down $2.33 during trading hours on Friday, reaching $53.67. The company had a trading volume of 584,623 shares, compared to its average volume of 929,528. The stock has a market capitalization of $8,250.00, a price-to-earnings ratio of -48.35 and a beta of 1.94. Alkermes has a 52-week low of $46.42 and a 52-week high of $64.04. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.72 and a current ratio of 3.05.
In other news, Director Paul J. Mitchell sold 1,000 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $56.77, for a total value of $56,770.00. Following the completion of the sale, the director now directly owns 9,000 shares of the company’s stock, valued at approximately $510,930. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Shane Cooke sold 1,700 shares of the business’s stock in a transaction dated Friday, January 26th. The shares were sold at an average price of $60.02, for a total value of $102,034.00. Following the completion of the sale, the insider now directly owns 76,408 shares of the company’s stock, valued at $4,586,008.16. The disclosure for this sale can be found here. Insiders sold a total of 135,485 shares of company stock valued at $8,227,502 over the last three months. Company insiders own 5.34% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. Toronto Dominion Bank increased its position in Alkermes by 12.7% in the 2nd quarter. Toronto Dominion Bank now owns 1,875 shares of the company’s stock valued at $109,000 after acquiring an additional 212 shares during the period. SG Americas Securities LLC acquired a new position in Alkermes in the 4th quarter valued at about $114,000. Quantbot Technologies LP acquired a new position in Alkermes in the 3rd quarter valued at about $126,000. Virtu Financial LLC acquired a new position in Alkermes in the 3rd quarter valued at about $201,000. Finally, M&T Bank Corp acquired a new position in Alkermes in the 4th quarter valued at about $221,000. 99.31% of the stock is owned by institutional investors and hedge funds.
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.